Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin David P. Ryan, Richard T. Penson, Sabrina Ahmed, Bruce A. Chabner, Thomas J. Lynch, Jr. Oncologist 1999; 4: 501-508 Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in risk management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Appreciate the emotive, ethical, and practical issues surrounding the initial clinical trials of high-profile novel treatments. Understand the dilemmas inherent in phase I clinical trials from both the perspective of staff and patients. Understand the responsibility of staff to support patients without compounding hype or suffocating hope. Note that this CME module is approved for specific CME credit in risk management, a requirement of licensure in some states. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 16, 2002 Most Recent Review: May 15, 2007* Most Recent Update: Apr. 16, 2002 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course